Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

Related Citations for PubMed (Select 22008051)

1.

Pharmacogenetics in randomized controlled trials: considerations for trial design.

van der Baan FH, Klungel OH, Egberts AC, Leufkens HG, Grobbee DE, Roes KC, Knol MJ.

Pharmacogenomics. 2011 Oct;12(10):1485-92. doi: 10.2217/pgs.11.95.

PMID:
22008051
2.

Potential of adaptive clinical trial designs in pharmacogenetic research.

van der Baan FH, Knol MJ, Klungel OH, Egberts AC, Grobbee DE, Roes KC.

Pharmacogenomics. 2012 Apr;13(5):571-8. doi: 10.2217/pgs.12.10.

PMID:
22462749
3.

Prospective alpha allocation in the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.

Joo J, Geller NL, French B, Kimmel SE, Rosenberg Y, Ellenberg JH.

Clin Trials. 2010 Oct;7(5):597-604. doi: 10.1177/1740774510381285. Epub 2010 Aug 6.

4.

Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.

Colditz GA.

Crit Rev Food Sci Nutr. 2010;50 Suppl 1:10-2. doi: 10.1080/10408398.2010.526838.

5.

Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.

Woods B, Veenstra D, Hawkins N.

Value Health. 2011 Dec;14(8):989-1001. doi: 10.1016/j.jval.2011.05.048. Epub 2011 Nov 12.

PMID:
22152167
7.

Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.

French B, Joo J, Geller NL, Kimmel SE, Rosenberg Y, Anderson JL, Gage BF, Johnson JA, Ellenberg JH; COAG (Clarification of Optimal Anticoagulation through Genetics) Investigators.

Trials. 2010 Nov 17;11:108. doi: 10.1186/1745-6215-11-108.

8.

The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.

Brugts JJ, de Maat MP, Boersma E, Witteman JC, van Duijn C, Uitterlinden AG, Bertrand M, Remme W, Fox K, Ferrari R, Danser AH, Simoons ML; EUROPA-PERGENE investigators.

Cardiovasc Drugs Ther. 2009 Apr;23(2):171-81. doi: 10.1007/s10557-008-6156-1. Epub 2008 Dec 10.

PMID:
19082699
9.

Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial.

Carcas AJ, Borobia AM, Velasco M, Abad-Santos F, Díaz MQ, Fernández-Capitán C, Ruiz-Giménez N, Madridano O, Sillero PL; PGX-ACE Spanish Investigators Group.

Trials. 2012 Dec 13;13:239. doi: 10.1186/1745-6215-13-239.

10.

Beyond HERS: some (not so) random thoughts on randomized clinical trials.

Bush T.

Int J Fertil Womens Med. 2001 Mar-Apr;46(2):55-9.

PMID:
11374656
11.

Pharmacogenetic application in drug development and clinical trials.

Shi MM, Bleavins MR, de la Iglesia FA.

Drug Metab Dispos. 2001 Apr;29(4 Pt 2):591-5.

12.

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.

Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF; Couma-Gen Investigators.

Circulation. 2007 Nov 27;116(22):2563-70. Epub 2007 Nov 7.

13.

Lay public's understanding of equipoise and randomisation in randomised controlled trials.

Robinson EJ, Kerr CE, Stevens AJ, Lilford RJ, Braunholtz DA, Edwards SJ, Beck SR, Rowley MG.

Health Technol Assess. 2005 Mar;9(8):1-192, iii-iv.

14.

Design issues in randomized phase II/III trials.

Korn EL, Freidlin B, Abrams JS, Halabi S.

J Clin Oncol. 2012 Feb 20;30(6):667-71. doi: 10.1200/JCO.2011.38.5732. Epub 2012 Jan 23.

15.

A review on the design and reporting of studies on drug-gene interaction.

Smits KM, Schouten JS, Smits LJ, Stelma FF, Nelemans P, Prins MH.

J Clin Epidemiol. 2005 Jul;58(7):651-4. Epub 2005 Apr 18. Review.

PMID:
15939214
16.

Experimental designs for small randomised clinical trials: an algorithm for choice.

Cornu C, Kassai B, Fisch R, Chiron C, Alberti C, Guerrini R, Rosati A, Pons G, Tiddens H, Chabaud S, Caudri D, Ballot C, Kurbatova P, Castellan AC, Bajard A, Nony P; CRESim & Epi-CRESim Project Groups, Aarons L, Bajard A, Ballot C, Bertrand Y, Bretz F, Caudri D, Castellan C, Chabaud S, Cornu C, Dufour F, Dunger-Baldauf C, Dupont JM, Fisch R, Guerrini R, Jullien V, Kassaï B, Nony P, Ogungbenro K, Pérol D, Pons G, Tiddens H, Rosati A, Alberti C, Chiron C, Kurbatova P, Nabbout R.

Orphanet J Rare Dis. 2013 Mar 25;8:48. doi: 10.1186/1750-1172-8-48. Review.

17.

Bone graft substitutes for the treatment of traumatic fractures of the extremities.

Hagen A, Gorenoi V, Schönermark MP.

GMS Health Technol Assess. 2012;8:Doc04. doi: 10.3205/hta000102. Epub 2012 Jun 14.

18.

Pharmacogenetics in drug regulation: promise, potential and pitfalls.

Shah RR.

Philos Trans R Soc Lond B Biol Sci. 2005 Aug 29;360(1460):1617-38. Review.

19.

Using multiple drug exposure levels to optimize power in pharmacogenetic trials.

Judson R.

J Clin Pharmacol. 2003 Aug;43(8):816-24. Review.

PMID:
12953338
20.

Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).

Brettschneider C, Lühmann D, Raspe H.

GMS Health Technol Assess. 2011 Feb 2;7:Doc01. doi: 10.3205/hta000092.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk